US 11,753,404 B2
Aminothiazole compounds as c-Kit inhibitors
Nicholas E. Bencivenga, Cambridge, MA (US); David C. Dalgarno, Cambridge, MA (US); Joseph M. Gozgit, Cambridge, MA (US); Wei-Sheng Huang, Cambridge, MA (US); Anna Kohlmann, Cambridge, MA (US); Feng Li, Cambridge, MA (US); Jiwei Qi, Cambridge, MA (US); William C. Shakespeare, Cambridge, MA (US); Ranny M. Thomas, Cambridge, MA (US); Yihan Wang, Cambridge, MA (US); and Xiaotian Zhu, Cambridge, MA (US)
Assigned to Ariad Pharmaceuticals, Inc., Cambridge, MA (US)
Filed by Ariad Pharmaceuticals, Inc., Cambridge, MA (US)
Filed on Apr. 9, 2021, as Appl. No. 17/226,531.
Application 17/226,531 is a continuation of application No. 16/469,517, granted, now 11,001,580, previously published as PCT/US2017/066291, filed on Dec. 14, 2017.
Claims priority of provisional application 62/434,845, filed on Dec. 15, 2016.
Prior Publication US 2022/0033392 A1, Feb. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 417/14 (2006.01); C07D 417/12 (2006.01); C07D 277/46 (2006.01); C07D 417/04 (2006.01)
CPC C07D 417/14 (2013.01) [C07D 277/46 (2013.01); C07D 417/04 (2013.01); C07D 417/12 (2013.01)] 4 Claims
1. A compound having one of the following formulae (Ig) or (Ih):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein
R1 is H;
R2 is —C(O)NR9R10;
R3 is (C1-C6) alkyl or halogen;
R4 is (C1-C6) haloalkyl;
R5 is H;
R9 and R10 together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocycloalkyl ring comprising 1 to 3 heteroatom selected from N, O, and S, optionally substituted with one or more substituents each independently selected from (C1-C6) alkyl, (C1-C6) hydroxyalkyl, -(CH2)q—(C1-C6) dialkylamino, —C(O)(C1-C6) alkyl, OH, or 6-membered heterocycloalkyl comprising 1 to 3 heteroatom selected from N, O, and S, and optionally substituted with (C1-C6) alkyl; and
q is 0, 1 or 2.